TruScreen Reports 523% Sales Growth for First Half Year

TruScreen Reports 523% Sales Growth for First Half Year

16 October 2018

• Sales for the six months ending 30 September 2018 tops NZD $1,406,932
(unaudited)
• 522.8% increase on the corresponding period last year (NZD $225,896)
• Gross margin increasing as in-house manufacturing lowers unit costs

Cervical cancer screening company, TruScreen Limited (NZAX: TRU) is reporting significant
commercial progress for the second quarter of its financial year, with a number of major events
driving adoption of the TruScreen technology.
CEO, Martin Dillon, said: “Sales of both devices and the disposal Single Use Sensors are tracking well
ahead of last year, with ongoing demand from China and other markets. We have a number of
growth initiatives in place and the recent $3 million capital raising, which was well supported by new
and existing shareholders, is providing a platform to support growth initiatives.”
China remains the primary market for TruScreen with growing demand and a number of initiatives
underway.
• TruScreen’s devices are selected as the primary screening tool for up to 50 planned women’s
health clinics and TruScreen has now been installed in the first eight of these.
• A large scale evaluation with The Women’s and Children’s Division of the Centre for Disease
Control has commenced and is expected to be completed by the end of the 2019 financial
year. This involves a minimum of 12,000 women across eight provinces and 16 hospitals in
China, with 1,500 patients already screened.
• Lastly, the company has announced a major programme in Xinjiang Province, which will see
TruScreen installed in 190 hospitals.
In Africa, an initial sale of approximately NZ$450,000 has been supplied to the National Aids Council
(NAC) of Zimbabwe which is supporting the use of TruScreen as the preferred screening method for
cervical cancer of HIV affected women. African countries represent a major untapped market
opportunity for the company, as many have little or no laboratory infrastructure or existing
screening programmes or methods. TruScreen’s portability and real time diagnosis means it is
perfectly suited for countries throughout the African continent.
The company’s new enhanced manufacturing facility, commissioned in June this year, is now fully
operational and delivering significant improvements in output and unit cost reduction. The facility
produces the key technical diagnostic (front end) component of the Truscreen2 device and involves
unique and sophisticated opto-electric and biomedical engineering skills and techniques.

ENDS
For more information visit www.truscreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com
Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505


About TruScreen:
TruScreen’s real time cervical cancer
technology utilises a digital wand which is
placed on the surface of the cervix to measure
electrical and optical signals from the
surrounding tissue. A sophisticated proprietary
algorithm framework distinguishes between
normal and abnormal (cancerous and
precancerous) tissue to identify precancerous
change, or cervical intraepithelial neoplasia
(CIN). A Single Use Sensor (SUS) is used for
each patient to protect against cross-infection.
For more information, visit our website at www.truscreen.com
Watch our video on TruScreen http://truscreen.com/truscreen-the-company/truscreen-ultra-video/